Aptar expanded its pharma operations in Mumbai, India, adding local production of several pharma inhalation technologies, including Aptar’s pressurized metered dose inhaler (pMDI) valve, as well as breath-actuated systems and multi dose nasal spray systems.

The investment reinforces Aptar’s long-term commitment to India as a strategic growth market and strengthens its ability to serve customers in India and across Southeast Asia with greater agility, reliability and proximity.

An inauguration ceremony held on October 5, 2026, marked the opening of the expanded operations at Aptar Pharma’s Mumbai site.

Inauguration ceremony of the expanded Aptar Pharma’s Mumbai site.

The facility was inaugurated by the Chairperson of the Aptar Board of Directors and members of Aptar’s Executive Committee, underscoring the importance of India within Aptar’s global growth strategy and the company’s commitment to expanding its presence in the region.

With the expansion, Aptar’s manufacturing footprint in Mumbai has increased to 11,300m2, adding molding capability in addition to the already existing assembly operations. The latest investment broadens the site’s role to support evolving customer needs while enhancing local capability and supply resilience.

India as a strategic growth market

Since establishing its commercial presence in Mumbai in 1998, Aptar has continuously expanded its footprint in India.

Timeline of Aptar’s footprint in India:

2012 – Aptar established local operations with its first assembly facility in Rabale.

2020 – Aptar opened a manufacturing site in Hyderabad to serve the consumer packaged goods markets.

2023 – Aptar opened a new state-of-the-art pharma manufacturing site in Taloja.

Additionally, India’s rapid urbanization, expanding healthcare access, manufacturing and digital infrastructure investments, and rising disposable incomes create further opportunities for Aptar.